Coenzyme Q10 in cardiovascular disease.
In this review we summarise the current state of knowledge of the therapeutic efficacy and mechanisms of action of CoQ(10) in cardiovascular disease. Our conclusions are: 1. There is promising evidence of a beneficial effect of CoQ(10) when given alone or in addition to standard therapies in hypertension and in heart failure, but less extensive evidence in ischemic heart disease. 2. Large scale multi-centre prospective randomised trials are indicated in all these areas but there are difficulties in funding such trials. 3. Presently, due to the notable absence of clinically significant side effects and likely therapeutic benefit, CoQ(10) can be considered a safe adjunct to standard therapies in cardiovascular disease.
Pepe
Salvatore
S
CJOB Department of Cardiothoracic Surgery, Alfred Hospital, Melbourne, Australia.
Marasco
Silvana F
SF
Haas
Steven J
SJ
Sheeran
Freya L
FL
Krum
Henry
H
Rosenfeldt
Franklin L
FL
D000255:Adenosine Triphosphate / Q000737:chemistry; D018943:Anthracyclines / Q000378:metabolism; D000975:Antioxidants / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003067:Coenzymes / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use; D004032:Diet; D006333:Heart Failure / Q000378:metabolism; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000378:metabolism; D006973:Hypertension / Q000188:drug therapy; D007511:Ischemia / Q000473:pathology; D008928:Mitochondria / Q000378:metabolism; D008954:Models, Biological; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000502:physiology / Q000627:therapeutic use
D018943:Anthracyclines; D000975:Antioxidants; D003067:Coenzymes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014451:Ubiquinone; D000255:Adenosine Triphosphate; C024989:coenzyme Q10